Rovi
Spanish Pharmaceutical Company
BME Madrid
ISIN ES0157261019 LEI 95980020140005936480
Follow Rovi
Weekly email: filings, results
Revenue, last year
€743.5M
−2.7% vs prior year
Net income
€140.4M
+2.6% vs prior year
EPS, diluted
€2.75
+3% vs prior year
Operating cash flow
€187.1M
+35.3% vs prior year
Source: ESEF annual reports · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | €743.5M | €140.4M |
| FY24 | €763.7M | €136.9M |
| FY23 | €829.5M | €170.3M |
| FY22 | €817.7M | €199.7M |
| FY21 | €648.7M | €153.1M |
| FY20 | €420M | €61.1M |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | 25% | 18.9% |
| FY24 | 23.5% | 17.9% |
| FY23 | 26.6% | 20.5% |
| FY22 | 31.3% | 24.4% |
| FY21 | 28% | 23.6% |
| FY20 | 17.8% | 14.5% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | €121.9M |
| FY24 | €79.2M |
| FY23 | €59.5M |
| FY22 | €186.9M |
| FY21 | €109.2M |
| FY20 | €7.5M |
- Dividends
- Buybacks
Show the numbers
| Year | Dividends | Buybacks |
|---|---|---|
| FY25 | €47.8M | €54.9M |
| FY24 | €56.5M | €89.7M |
| FY23 | €69M | €133.9M |
| FY22 | €51M | €177M |
| FY21 | €21.1M | €78.8M |
| FY20 | €9.7M | €37.3M |
- Rovi
- Healthcare median
Show the numbers
| Year | Rovi | Healthcare median |
|---|---|---|
| FY25 | 18.9% | −30.6% |
| FY24 | 17.9% | −47% |
| FY23 | 20.5% | −58% |
| FY22 | 24.4% | −80.4% |
| FY21 | 23.6% | −71.9% |
| FY20 | 14.5% | −62.2% |